A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for metastatic
triple-negative breast cancer.
The drugs involved in this study are:
- Cabozantinib (XL184)
- Nivolumab